Compile Data Set for Download or QSAR
Report error Found 367 Enz. Inhib. hit(s) with all data for entry = 10028
TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191570(US9670204, 12 2-((2-ethyl-8-fluoro-6-(4-(2-(3-hydr...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191618(US9670204, 22 2-(4-(3-((5-cyano-4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191784(US9670204, 30 1-(azetidin-1-yl)-2-(4-(2-ethyl-3-((...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191788(US9670204, 31 2-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192616(US9670204, 115 2-(4-(2-ethyl-3-((4-(4-fluorophenyl...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM509394(US11072611, Compound 138)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM509395(US11072611, Compound 139)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192945(US9670204, 140 2-(4-(3-((5-cyano-4-(4-fluorophenyl...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192946(US9670204, 141 2-((2-ethyl-6-(1-(2-(3-hydroxyazeti...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM426505(US10526329, Compound 142 | US11072611, Compound 14...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM426506(US10526329, Compound 143 | US11072611, Compound 14...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192949(US9670204, 144 2-((2-ethyl-6-(1-(2-(3-(hydroxymeth...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192950(US9670204, 145 2-(4-(3-((5-cyano-4-(4-fluorophenyl...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192979(US9670204, 159 1-(2-((2-ethyl-6-(1-(2-(3-hydroxyaz...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192984(US9670204, 164 2-(2-((2-ethyl-6-(4-(2-(3-fluoroaze...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192986(US9670204, 166 2-(2-((2-ethyl-6-(4-(2-(3-hydroxyaz...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192987(US9670204, 167 2-(2-((6-(4-(2-(azetidin-1-yl)-2-ox...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192988(US9670204, 168 2-(4-(3-((4-(2-cyano-4-fluorophenyl...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192989(US9670204, 169 2-(4-(3-((4-(2-cyano-4-fluorophenyl...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192990(US9670204, 170 2-(2-((2-ethyl-6-(1-(2-(3-hydroxyaz...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192991(US9670204, 171 2-(4-(3-((4-(2-cyano-4-fluorophenyl...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192993(US9670204, 173 2-(5-((2-ethyl-6-(1-(2-(3-hydroxyaz...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM192994(US9670204, 174 2-(4-(2-(2-cyanoethyl)-3-((4-(4-flu...)
Affinity DataIC50: 50nMAssay Description:TABLE V: 5 μL of a dilution series of compound, starting from 20 μM highest concentration, 1/5 dilution, is added to the wells. hENPP2 is u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM50187686(CHEMBL3828074 | US9670204, 2 2-((2-ethyl-6-(4-(2-(...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191376(US9670204, 4 (R)-2-((2-ethyl-6-(4-(2-(3-hydroxypyr...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191384(US9670204, 5 (S)-2-((2-ethyl-6-(4-(2-(3-hydroxypyr...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191570(US9670204, 12 2-((2-ethyl-8-fluoro-6-(4-(2-(3-hydr...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191618(US9670204, 22 2-(4-(3-((5-cyano-4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191627(US9670204, 23 tert-butyl4-(2-ethyl-3-((4-(4-fluoro...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191765(US9670204, 24 2-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM509282(US11072611, Compound 25)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191781(US9670204, 27 N-(1-(2-(4-(2-ethyl-3-((4-(4-fluorop...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191792(US9670204, 35 2-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191794(US9670204, 36 ethyl2-(4-(2-ethyl-3-((4-(4-fluoroph...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191796(US9670204, 38 2-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191797(US9670204, 39 N-(6-(4-((1-cyclopropyl-1H-tetrazol-...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191806(US9670204, 40 N-(2-ethyl-6-(4-oxazol-2-ylmethyl)pi...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191807(US9670204, 41 N-(6-(4-((1,2,4-oxadiazol-3-yl)methy...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191808(US9670204, 42 2-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191811(US9670204, 43 2-hydroxyethyl4-(2-ethyl-3-((4-(4-fl...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191814(US9670204, 46 (4-(2-ethyl-3-((4-(4-fluorophenyl)th...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191815(US9670204, 47 (4-(2-ethyl-3-((4-(4-fluorophenyl)th...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191819(US9670204, 49 (4-(2-ethyl-3-((4-(4-fluorophenyl)th...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191820(US9670204, 50 1-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191824(US9670204, 51 1-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191829(US9670204, 52 1-(4-(2-ethyl-3-((4-(4-fluorophenyl)...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191830(US9670204, 53 4-(dimethylamino)-1-(4-(2-ethyl-3-((...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191831(US9670204, 54 N-(2-ethyl-6-(4-(methylsulfonyl)pipe...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191833(US9670204, 55 N-(6-(4-(3-chloropropylsulfonyl)pipe...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetAutotaxin(Human)
Galapagos

US Patent
LigandPNGBDBM191835(US9670204, 56 N-(6-(4-(3-(dimethylamino)propyl-sul...)
Affinity DataIC50: 50nMAssay Description:TABLE VI: (UniProtKB/SwissProt Sequence ref Q13822) biochemical assay using the fluorogenic autotaxin substrate FS-3 as substrate. FS-3 is a doubly l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 367 total ) | Next | Last >>
Jump to: